In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo, sunitinib helped in treatments for more than half of the patients in the study. This study showed an improvement of disease-free survival of 8%, which is comparable to other cancers, like breast and colon. A key aspect of the study was standardized dosage for the entire length of treatment, and non-standardized breaks in dosage to help manage toxicity. Dr. George goes on to discuss future treatments and upcoming studies.
View the video and learn more by clicking here.